

Malene Grubbe Hildebrandt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8483814/publications.pdf>

Version: 2024-02-01

35
papers

649
citations

777949

13
h-index

685536

24
g-index

35
all docs

35
docs citations

35
times ranked

836
citing authors

#	ARTICLE	IF	CITATIONS
1	Response monitoring in metastatic breast cancer: a comparison of survival times between FDG-PET/CT and CE-CT. <i>British Journal of Cancer</i> , 2022, 126, 1271-1279.	2.9	15
2	The diagnostic accuracy and clinical impact of FDG-PET/CT follow-up for patients on adjuvant immunotherapy for high-risk malignant melanoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2342-2351.	3.3	6
3	Abstract P5-07-07: Mapping clonal evolution and tumor heterogeneity by whole exome sequencing of tissue and plasma circulating tumor DNA in metastatic breast cancer. <i>Cancer Research</i> , 2022, 82, P5-07-07-P5-07-07.	0.4	0
4	Heterogeneity and tumor evolution reflected in liquid biopsy in metastatic breast cancer patients: a review. <i>Cancer and Metastasis Reviews</i> , 2022, 41, 433-446.	2.7	8
5	SENTIREC â€œ The sentinel node mapping in women with cervical cancer study â€œ Patient-reported early lymphedema and its impact on quality of life. <i>Gynecologic Oncology</i> , 2022, 164, 463-472.	0.6	6
6	A role of FDG-PET/CT for response evaluation in metastatic breast cancer?. <i>Seminars in Nuclear Medicine</i> , 2022, 52, 520-530.	2.5	19
7	How to increase value and reduce waste in research: initial experiences of applying Lean thinking and visual management in research leadership. <i>BMJ Open</i> , 2022, 12, e058179.	0.8	3
8	Hybrid PET/MRI in non-small cell lung cancer (NSCLC) and lung nodulesâ€”a literature review. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 584-591.	3.3	26
9	FDG-PET/CT in high-risk primary breast cancerâ€”a prospective study of stage migration and clinical impact. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 145-153.	1.1	16
10	FDG-PET/CT for Response Monitoring in Metastatic Breast Cancer: The Feasibility and Benefits of Applying PERCIST. <i>Diagnostics</i> , 2021, 11, 723.	1.3	10
11	Clinical Impact of FDG-PET/CT Compared with CE-CT in Response Monitoring of Metastatic Breast Cancer. <i>Cancers</i> , 2021, 13, 4080.	1.7	8
12	Benefits and harms of implementing [18F]FDG-PET/CT for diagnosing recurrent breast cancer: a prospective clinical study. <i>EJNMMI Research</i> , 2021, 11, 93.	1.1	14
13	From FIGO-2009 to FIGO-2018 in women with early-stage cervical cancer; Does the revised staging reflect risk groups?. <i>Gynecologic Oncology</i> , 2021, 163, 281-288.	0.6	7
14	Sentinel lymph node mapping in early-stage cervical cancer â€œ A national prospective multicenter study (SENTIREC trial). <i>Gynecologic Oncology</i> , 2021, 162, 546-554.	0.6	15
15	Diagnosis of bone metastases in breast cancer: Lesion-based sensitivity of dual-time-point FDG-PET/CT compared to low-dose CT and bone scintigraphy. <i>PLoS ONE</i> , 2021, 16, e0260066.	1.1	18
16	Clinical impact of preâ€”treatment FDGâ€”PET/CT staging of primary ovarian, fallopian tube, and peritoneal cancers in women. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2020, 99, 186-195.	1.3	7
17	Interrater Agreement and Reliability of PERCIST and Visual Assessment When Using 18F-FDG-PET/CT for Response Monitoring of Metastatic Breast Cancer. <i>Diagnostics</i> , 2020, 10, 1001.	1.3	10
18	Higher Interrater Agreement of FDG-PET/CT than Bone Scintigraphy in Diagnosing Bone Recurrent Breast Cancer. <i>Diagnostics</i> , 2020, 10, 1021.	1.3	1

#	ARTICLE	IF	CITATIONS
19	Prognostic Value of Dual-Time-Point 18F-Fluorodeoxyglucose PET/CT in Metastatic Breast Cancer: An Exploratory Study of Quantitative Measures. <i>Diagnostics</i> , 2020, 10, 398.	1.3	4
20	Learning from patient involvement in a clinical study analyzing PET/CT in women with advanced breast cancer. <i>Research Involvement and Engagement</i> , 2020, 6, 1.	1.1	41
21	Perspective of Patients with Metastatic Breast Cancer on Electronic Access to Scan Results: Mixed-Methods Study. <i>Journal of Medical Internet Research</i> , 2020, 22, e15723.	2.1	10
22	Hybrid PET/MRI in major cancers: a scoping review. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2138-2151.	3.3	31
23	FDG-PET/CT for Response Monitoring in Metastatic Breast Cancer: Today, Tomorrow, and Beyond. <i>Cancers</i> , 2019, 11, 1190.	1.7	12
24	FDG-PET/CT Versus Contrast-Enhanced CT for Response Evaluation in Metastatic Breast Cancer: A Systematic Review. <i>Diagnostics</i> , 2019, 9, 106.	1.3	9
25	Diagnostic manifestations of total hemispheric glucose metabolism ratio in neuronal network diaschisis: diagnostic implications in Alzheimer's disease and mild cognitive impairment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1164-1174.	3.3	5
26	Quantification of FDG-PET/CT with delayed imaging in patients with newly diagnosed recurrent breast cancer. <i>BMC Medical Imaging</i> , 2018, 18, 11.	1.4	9
27	Stewart-Treves Syndrome on the Lower Extremity Associated to Idiopathic Chronic Lymphedema Visualized on FDG PET/CT. <i>Clinical Nuclear Medicine</i> , 2017, 42, e519-e522.	0.7	7
28	Group-sequential analysis may allow for early trial termination: illustration by an intra-observer repeatability study. <i>EJNMMI Research</i> , 2017, 7, 79.	1.1	3
29	[¹⁸ F]Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET)/Computed Tomography (CT) in Suspected Recurrent Breast Cancer: A Prospective Comparative Study of Dual-Time-Point FDG-PET/CT, Contrast-Enhanced CT, and Bone Scintigraphy. <i>Journal of Clinical Oncology</i> , 2016, 34, 1889-1897.	0.8	64
30	[¹⁸ F]Fluorodeoxyglucose PET/Computed Tomography in Breast Cancer and Gynecologic Cancers. <i>PET Clinics</i> , 2015, 10, 89-104.	1.5	11
31	Delayed 18F-fluorodeoxyglucose PET/CT imaging improves quantitation of atherosclerotic plaque inflammation: Results from the CAMONA study. <i>Journal of Nuclear Cardiology</i> , 2014, 21, 588-597.	1.4	74
32	Low risk of recurrence in breast cancer with negative sentinel node. <i>Danish Medical Bulletin</i> , 2011, 58, A4255.	0.3	3
33	Gender and depression: a study of severity and symptomatology of depressive disorders (ICD-10) in general practice. <i>Acta Psychiatrica Scandinavica</i> , 2003, 107, 197-202.	2.2	33
34	Are Gender Differences Important for the Clinical Effects of Antidepressants?. <i>American Journal of Psychiatry</i> , 2003, 160, 1643-1650.	4.0	107
35	Gender Differences in Severity, Symptomatology and Distribution of Melancholia in Major Depression. <i>Psychopathology</i> , 2003, 36, 204-212.	1.1	37